{"id":128091,"date":"2025-09-04T20:09:07","date_gmt":"2025-09-04T20:09:07","guid":{"rendered":"https:\/\/todaysveterinarynurse.com\/?p=128091"},"modified":"2025-09-04T20:09:07","modified_gmt":"2025-09-04T20:09:07","slug":"embracing-the-beauty-of-change","status":"publish","type":"post","link":"https:\/\/navc.sitepreview.app\/todaysveterinarynurse.com\/personal-professional-development\/embracing-the-beauty-of-change\/","title":{"rendered":"Embracing the Beauty of Change"},"content":{"rendered":"

Autumn is a great time to open our minds to learning as we do for the changing season. With the fall season upon us, we can take the opportunity to curl up in a favorite blanket with our cat, dog, bird, or iguana and read the Today\u2019s Veterinary Nurse<\/i> Fall issue to learn a new technique for a skill or revisit one that we have not performed in a while! This issue covers the latest information veterinary nurses need to know about the ongoing <\/span>avian influenza outbreak<\/span><\/a> and the risk of <\/span>MDR1 mutations in our feline patients<\/span><\/a>. There is also a much-needed discussion on how <\/span>exercise is crucial to<\/span> managing weight <\/span><\/a>in our patients. Embrace the beauty that is autumn. Your knowledge and skill set will be better for it, and your patients will benefit. Change, like the autumn leaves, can be glorious!<\/span><\/p>\n

\n

What We\u2019re Reading<\/span><\/h3>\n

A member of our Editorial Advisory Board shares a recent open access publication, including their key takeaways and its practical conclusion.<\/i><\/p>\n

Efficacy, Safety, and Vaccine Response in Dogs Treated with Ilunocitinib (Zenrelia)<\/b><\/span><\/p>\n

Forster S, Trout CM, Despa S, Boegel A, Berger D, King S. Vet Dermatol<\/i>.
\n<\/span>https:\/\/doi.org\/10.1111\/vde.13344<\/i><\/span><\/a><\/p>\n

Fent GM, Jacela J, Plazola-Ortiz R, et al. BMC Vet Res<\/i>.
\n<\/span>https:\/\/doi.org\/10.1186\/s12917-025-04929-z<\/i><\/span><\/a><\/p>\n

Fent GM, Despa S, Gabor L, et al. BMC Vet Res<\/i>.
\n<\/span>https:\/\/doi.org\/10.1186\/s12917-025-04896-5<\/i><\/span><\/a><\/p>\n

WHAT WAS INVESTIGATED?<\/b> In follow-up to an initial safety trial, 2 studies evaluated ilunocitinib, a Janus kinase (JAK) inhibitor, for its ability to control pruritus and skin lesions in client-owned dogs with canine atopic dermatitis (CAD) and its effect on immune response to core booster vaccinations when given at up to 3 times the recommended dose.<\/p>\n

WHAT WAS DISCUSSED?<\/b><\/p>\n